Frequent allelic imbalances, including loss of heterozygosity (LOH) and microsatellite instability (MSI), have been found on the long arm of chromosome 21 (21q) in several types of human cancer. This study was designed to identify the tumor suppressor locus (or loci) associated with oral squamous cell carcinoma (SCC) on 21q. In order to understand the details of genetic alterations on chromosome 21, we performed polymerase chain reaction analysis of microsatellite polymorphisms corresponding to ten loci on this chromosome. We examined forty primary tumor tissues, forty corresponding normal tissues, and seven lymph node metastatic tissues. We identified novel tumor suppressor loci in this region in primary oral SCCs. To further determine the role of 21q deletions in oral cavity carcinogenesis, forty oral SCCs were examined for allelic imbalances (LOH or MSI) at 21q using ten microsatellite markers. Among these forty patients, twenty-six (65%) showed LOH at one or more loci. Deletion mapping of these tumors revealed four discrete, commonly deleted regions on the chromosome arm. Furthermore, we detected MSI in seventeen of those tested cases (42.5%). We compared our results with the clinicopathologic features. A number of sites displaying LOH at 21q could be detected in early stage lesions, and the frequencies of LOH tended to be higher in later clinical stages, but no statistical correlation was observed. Our results strongly suggest that allelic imbalances on 21q are involved in the development of oral SCC and that at least four different putative tumor suppressor genes contributing to the pathogenesis of this disease are present on 21q. Furthermore, allelic loss on 21q appears to be a useful indicator for evaluating the malignancy and prognosis of oral SCC, because the LOH of recurrent cases was more frequent than that of non-recurrent ones.
INTRODUCTION
Oral cancer is one of the most common malignancies worldwide. Although squamous cell carcinoma (SCC) comprises over 80% of all malignant tumors of the oral cavity, there is no effective tool for identifying cells possessing the cancerous phenotype within a normal squamous cell population and no useful genetic marker that contributes to determining the clinical malignancies of oral SCC. Despite its clinical relevance, very little is known about the molecular basis of oral SCC, compared to other human malignancies.
Inactivation of tumor suppressor genes and activation of oncogenes have been shown to play important roles in the multi-step process of human carcinogenesis 6) . For example, allelic imbalances including loss of heterozygosity (LOH) and microsatellite instability (MSI) 13, 24) in malignant cells have proven useful for mapping DNA regions potentially harboring candidate tumor suppressor genes 42) . Studies based upon the somatic LOH have led to the discovery of several such genes, including RB, p53, WT, CDKN2A, APC, DPC4, FHIT and PTEN 3, 4, 8, 9, 11, 14, 17, 27, 34) . In oral SCCs, high frequencies of LOH have been detected on several chromosome arms, including 3p, 4q, 5q, 7q, 8p, 9p, 11q, 13q, 18q, 20q and 22q 12, 21, 23, 25, 28, 29, [36] [37] [38] [39] [40] [41] , where candidate tumor suppressor genes may be present. Thus, many possible tumor suppressor genes that have not been characterized may be associated with the development of human oral cancer.
Recent allelotype analyses in certain human carcinomas other than oral cancer have identified specific deleted regions on 21q in cases of ovarian cancer, lung cancer, esophageal cancer, renal cell carcinoma, gastric cancer, and breast cancer ( Fig. 1 ) 2, 5, 15, 20, 26, [30] [31] [32] , suggesting that one or more tumor suppressor gene(s) specific to several types of human cancer may exist on 21q. We have hypothesized the existence of new tumor suppressor gene(s) specific to oral SCC on this chromosome arm; recently, we reported frequent LOH on 21q in primary oral SCC samples, and three distinct tumor suppressor gene loci were identified 45) . The most frequently deleted region was mapped to 21q11.1.
Recently, a candidate tumor suppressor gene abundant in neuroepithelium area gene (ANA) was identified and mapped to 21q11.2-q21.1 47) . In the same study, homozygous deletion of the ANA gene was found in a human non-small-cell lung carcinoma (NSCLC), whereas no mutation of the gene was detected in primary NSCLCs 47) . Given the high frequency of LOH in this region, we hypothesized that the ANA gene is one of the target genes for examining the development of human oral SCC 46) . In the present study, as a first step toward the isolation of the putative suppressor gene(s) associated with oral SCC on 21q, we examined eighty-seven tissue samples from forty patients with various grades of oral SCC. By comparing the results obtained from tumor and normal DNA, a detailed deletion map of the chromosome arm was constructed. The following were N. YAMAMOTO et al. evaluated: 1) identification of novel putative suppressor gene(s) loci particular to oral SCC; 2) specification of the tumor genetic marker(s); 3) relationships between clinicopathologic features and assessment of malignancy.
MATERIALS AND METHODS

Tissue samples
Sample tissues were available from forty patients with oral SCC who came to the Department of Oral and Maxillo-facial Surgery, Tokyo Dental College Chiba Hospital, during the four years between 1997 and 2000 (Table 1 ). All cases were observed for at least one year after operation. Informed consent was obtained from all patients and also from their families. The tissue samples were forty primary tumors and forty normal tissues corresponding to these primary tumors. Seven metastatic tissues were available from lymph node metastasis. They were collected either at the time of surgical resection (no chemotherapy and radiotherapy before surgical resection in any case) or at the time of biopsy.
The resected tissues were divided into two segments; one was frozen immediately after careful removal from the surrounding normal tissues and stored at ‫°08מ‬C until extraction of DNA, and the other was fixed in 10% formalin for pathologic diagnosis. Histopathologic diagnosis was performed according to the International Classification of Tumors 43) by the Department of Pathology, Tokyo Dental College. Clinicopathologic staging was determined by the UICC TNM staging system 35) .
DNA extraction
All patients had histologically confirmed SCC of the oral cavity, and the tumor samples for DNA extraction were checked to ensure that they consisted of more than 80% tumor. All tumor samples and most normal tissue samples were processed from fresh-frozen specimens that had been preserved in liquid nitrogen immediately after resection. First, the tissues were powdered with liquid nitrogen. Then, after they had been spun down to be deposited once, genomic DNAs were added to TNES buffer 1,500l (10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 10 mM EDTA, 0.1% SDS) and Proteinase K 45l (100g/ml), stirred, digested, and incubated in the waterbath overnight at 50°C. After DNAs were extracted by phenol-chloroform extraction and refined, they were washed and precipitated with ethanol 19) . The concentrations of extracted DNA were estimated by a spectrophotometric method and kept frozen at ‫°08מ‬C. From each DNA sample, 50 ng/l were used for the template of the polymerase chain reaction (PCR) amplification procedure.
PCR and microsatellite analysis
We examined whether these were tumor suppressor genes which concerned with the generation and development of oral SCC or not. We used ten microsatellite markers among those on 21q (D21S1433, D21S369, D21S1231, D21S258, D21S236, D21S120, D21S1256, D21S11, D21S1436 and D21S1254: Research Genetics), based on reports of high frequent LOH for other cancers 2, 5, 15, 20, 26, [30] [31] [32] . PCR amplification was performed in a total reaction volume of 20l, as described previously 16) . Each PCR reaction mixture contained 250 ng of sample DNA, 20 pmol of each primer, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 3.0 mM MgCl 2 , 2 mM dNTP, and 0.5 unit of Taq DNA polymerase (Perkin-Elmer, Norwalk, CT). Thirtyfive cycles of denaturation at 94°C for 1 min, annealing at 55°C for 1 min, and extension at 72°C for 1 min were performed with a DNA Thermal Cycler (Perkin-Elmer). After dilution with an adequate volume of formamide-dye mixture (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, and 0.05% xylene cyanol), the PCR products were heat-denatured (98°C, 5 min), chilled on ice, and electrophoresed on 6% urea-formamide-polyacrylamide gel at 3W for 2 to 3 hours, depending on the fragment size. Silver staining of the gels were performed using the DNA Silver Staining Kit (Amersham Pharmacia Biotech AB Sweden). To ensure the reproducibility in each case showing LOH or MSI, all tests were performed under the same conditions. ; 21 were grade 3, and 19, grade 4C. The progressions obtained were: 24 well progression and 16 poor progression (5 cases of death, 4 of recurrence, and 7 of lymph node or distant metastasis).
Statistical analysis
We used Fisher's exact test to analyze for significance of differences in frequencies of LOH and MSI between clinical and histopathological features such as gender, region, T classification, TNM staging, histopathological The case number is shown above each column, and the ten microsatellite markers are on the left. required for LOH. Commonly deleted regions were defined by considering the loci most frequently showing LOH, together with multiple interstitial deletions. MSI for DNA samples was also assessed as positive when there were additional bands in the tumor sample that were not observed in the corresponding normal sample or there was a band shift in the tumor sample that contrasted with those of the corresponding normal bands.
Clinicopathologic findings
The subjects were twenty-four males and sixteen females. The average ages were 63.1 years old for males (between 41 and 80 years old), 63.8 years old for females (between 26 and 85 years old), and 63.5 years old for all (between 26 and 85 years old). The regions affected were: sixteen tongues, fourteen gingivas, four oral floors, three buccal mucosas, and three soft palates. T classifications to indicate the sizes of the primary clinical tumors were: 7 T1, 17 T2, 10 T3, and 6 T4. The classifications of differentiation, lymph node metastasis in histopathology, mode of invasion, and progression. The accepted level was pϽ0.05.
RESULTS
Assessment of LOH and MSI
A total of eighty-seven tissue samples from forty patients with oral SCC was studied for N. YAMAMOTO et al.
LOH and MSI using ten high polymorphic markers mapped on 21q. The forty cases observed in this study were all informative for some of the markers. Of the cases that were informative for at least one of the loci, twentysix (65%) showed LOH. MSI was observed in seventeen of forty cases (42.5%) in the present study. The most frequent MSI was identified at the marker D21S1433 (17.4%). Deletion mapping of these forty tumors revealed four discrete, commonly deleted regions on the chromosome arm (Fig. 2) . Frequent allelic deletion was observed at loci on D21S369 (52.4%) and D21S236 (28.9%) at 21q11.1, D21S11 (21.6%) at 21q21, and D21S1254 (22.2%) at 21q22.1 (Fig. 3 , Table 2 ). Among them, two loci, D21S11 and D21S1254, have already been reported as candidate tumor suppressor gene loci for gastric cancer 30) . We have thus identified herein two novel, commonly deleted regions of the markers D21S369 and D21S236 at 21q11.1 in oral SCC; these have not been reported as putative tumor suppressor loci in any other type of human cancer. The results of LOH frequencies for the other markers were as follows; D21S1433 (13.0%) at 21p-q, D21S1231 (7.1%) and D21S258 (17.9%) at 21q11.1, D21S120 (4.0%) at 21q11.1-21, and D21S1256 (11.8%) and D21S1436 (17.5%) at 21q21 (Fig. 3, Table 2 ). Typical examples of allelic imbalances (LOH and MSI) on 21q are shown in Fig. 4 . In addition, microsatellites from lymph node metastatic tumor tissues of seven cases were analyzed. LOH was observed in five of them (71.4%) (Fig. 5, 6 ).
LOCALIZATION OF A TUMOR SUPPRESSOR GENE ASSOCIATED WITH HUMAN ORAL CANCER ON 21Q
Clinicopathologic analysis
The results included the following: (Table 3) The frequency in LOH was 75% for males, which was higher than that for females. The frequency of occurring in the tongue was 75%, which was higher than that in gingiva or oral floor. T2 and Stage II were the most common of T classifications and classifications of TNM stage; the former and the latter LOH were 88.2% and 85.7% respectively. The highest LOH was recognized in well differentiated tumors at 67.7% among tumor differentiations. LOH of 63.6% in pN(‫)ם‬ was slightly more than in pN(‫.)מ‬ LOH of 71.4% in grade 3 was higher than in grade 4C in the mode of invasion.
LOH was observed in 13 of 24 well progressing cases (54.2%) and in 13 of 16 poorly progressing cases (81.3%), among which 5 cases were recurrence or in the process of distant metastasis, and 4 of 5 had died (80%). MSI was observed in 12 of 24 well progressing cases (50%) and in 5 of 16 poorly progressing cases (31.3%), among which 5 cases had poor prognoses and 2 cases had died (40%).
The Fisher's exact test was performed to evaluate possible significant correlations between allelic imbalances (LOH and MSI) and clinicopathologic parameters. No statistically significant correlations were observed.
Findings for typical examples with clinically high malignancy
The three representative cases of particularly high frequency in primary tumors and lymph node metastasis were evaluated on the basis of clinicopathologic features and allelic imbalances.
Case 8 was a 64-year-old male with tongue SCC (T2N2bM0), Stage IV, well differentiated, pN(‫,)ם‬ grade 3 of mode of invasion, recurrence, and death. This case was informative in the investigation for all ten markers. LOH and MSI were found in a high frequency of seven of ten (70%) markers.
Case 30 was a 41-year-old male with gingiva SCC (T4N2bM0), Stage IV, well differentiated, pN(‫,)מ‬ grade 4C of mode of invasion, distant metastasis, and death. LOH and MSI were found at a high frequency of six of seven informative (85.7%) markers.
Case 19 was a 78-year-old female with gingiva SCC (T4N2bM0), Stage IV, well differentiated, pN(‫,)ם‬ grade 3 of mode of invasion, recurrence, and death. This case was informative in the investigation for all ten markers. LOH and MSI were found in a high frequency of seven (70%) of ten informative markers. All three cases had characteristically destructive invasion.
DISCUSSION
Carcinogenesis is a multistep process in which several genetic alterations occur. Many oncogenes and tumor suppressor genes are considered to be involved in this sequence. The inactivation of tumor suppressor genes seems to be important in the etiology of oral cancers 6) . One strategy for locating putative tumor suppressor genes is to survey tumors for high rates of LOH. Previous allelotype studies on many human chromosomes have been the source of considerable information in the analysis of human tumors 1) . Among them, LOHs are found in various chromosomes in the oral region 1, 7, 33) . LOH is observed at high frequency especially in 3p. Although LOCALIZATION OF A TUMOR SUPPRESSOR GENE ASSOCIATED WITH HUMAN ORAL CANCER ON 21Q Table 3 Relationship between allelic imbalances and clinicopathological features on 21q few studies on chromosome 21q have been conducted in the oral region, the result of study on 3p 36) shows less frequency and fewer cases than the results of our study on 21q.
Frequency of allelic imbalance on chromosome 21q
We have confirmed that chromosome 21q-allelic imbalances defined as LOH and/or MSI are associated with the development of oral SCC. Twenty-six of forty (65%) informative oral SCC cases examined in this study showed LOH at one or more loci. Deletion mapping of these forty tumors revealed four discrete, commonly deleted regions on the chromosome arm. Chromosomes loci in the regions of D21S369 and D21S236 on 21q11.1, D21S11 on 21q21, and D21S1254 on 21q22.1 loci seemed to have highly frequent LOH.
Recently, Sakata et al. 30) constructed a detailed deletion map of 21q in gastric cancer and found two commonly deleted regions at markers D21S1254 and D21S1456. More recently, Ohgaki et al. 26) identified a commonly deleted region spanning six centi-morgans at 21q21 in breast cancer; this overlapped the proximal commonly deleted region in gastric cancer. These observations suggest that more than one tumor suppressor gene specific to several types of human malignancy may exist on 21q. In our previous study, three potential tumor suppressor gene loci were identified on 21q in oral SCCs 45) . Of them, the most frequently deleted region was identified between D21S11 and D21S1436 on chromosome band 21q21, where frequent LOHs have also been reported in gastric cancer 30) . These observations suggest that a putative tumor suppressor gene associated with oral SCC as well as gastric cancer is located at this region. We found a different, commonly deleted region at marker D21S1254 mapped to 21q22.1. Interestingly, this locus includes several genes such as TIAMI, AMLI, and IFNAR 10, 18, 22) . According to previous studies, those genes seem to be someone associated with the development of human cancer 10, 18, 22) . In this study, based upon our deletion map of the chromosome, four discrete candidate regions appear to contain oral SCC tumor suppressor genes. Of them, the most frequently deleted region was identified on 21q11.1, which is near the ANA gene locus. The discovery of homozygous deletion of the ANA gene in a lung cancer cell line is thus also of interest because of its chromosomal localization on 21q11.2-q21.1 15) . In the present study, we extended these initial observations and identified two novel commonly deleted regions that are distinct from and centromeric to the ANA locus. Interestingly, these regions are clearly different from the commonly deleted regions identified in gastric or breast cancer. Therefore, these data suggest that there may be new target genes at 21q11.1 and that these genes may be specifically associated with the pathogenesis of human oral SCCs.
Relationship between allelic imbalances and clinicopathologic features in oral SCC
We statistically analyzed the correlation between the results of 21q-abnormalities and the clinicopathologic features of the tumors. No statistically significant correlations were found between the present of LOH and clinical stage or histological grade of the patients in the present study. These results suggest that inactivation of the tumor suppressor gene is an initial step of carcinogenesis in oral SCC. When, DNAs from the metastatic tissues of seven patients were analyzed, LOH was found in five of seven cases (71.4%). However, because our sample was small, we were unable to demonstrate a statistically significant difference between metastatic and non-metastatic tumors. More extensive genetic analysis with a greater number of metastatic oral SCC samples will be important for addressing this problem.
In this study, MSI on 21q was also examined in our oral SCC cases. Overall, the frequency was 42.5% (seventeen of forty cases). Interestingly, the incidence of MSI at D21S1433 was the highest among the microsatellite markers tested; this is a site where frequent LOH was also detected. Thus, our results suggest that this locus may be the most fragile site on this chromosome arm in oral SCC and/or that LOH here may reflect the genomic instability of the disease. Furthermore, these results suggest that inactivation of this tumor suppressor gene is an initial step of carcinogenesis in oral SCC, although no correlation between MSI and clinical stage or differentiation was observed. Thus, it could not be determined from our study whether MSI at 21q is an important prognostic indicator.
Typical examples of clinically high
malignancy and poor prognosis in primary tumors and lymph node metastasis High frequencies of LOH and MSI were observed in the examples of clinically high malignancy and poor prognosis. Furthermore, all these cases ended with death.
Accordingly, evaluation of the LOH and MSI of 21q may be useful in predicting the malignancy and prognosis of this disease.
High frequencies of LOH and MSI were also observed in lymph node metastasis. Thus, this study may serve as useful estimate of metastasis of oral SCC.
In conclusion, we have identified four different tumor suppressor gene loci, including a novel deleted region, on 21q11.1 in oral SCC and have also found frequent LOH and MSI on this chromosome arm. These may serve as useful markers for the evaluation of this disease.
Furthermore, our study suggests that allelic deletion of 21q loci plays a role in oral SCC progression. In particular, the regions of D21S369, D21S236, D21S11 and D21S1254 have more significant roles than the others examined in this study.
Based on our present knowledge and experience, we would advocate wider resection margins and prophylactic treatment of the neck by surgery or radiotherapy to give these patients the best possible chance of long-term survival. Frequent, meticulous follow-up is also indicated. At present, there is no proven adjuvant therapy that can reduce the risk of distant metastasis in patients treated for oral cancer. Prospective studies using microsatellite analysis on 21q should be initiated for this subgroup of patients.
